ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Segment A, participants will acquire various doses and schedules of oral ABBV-744 pill to identify safe dosing routine. Added individuals will probably be enrolled in the identified monotherapy dosign routine. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will probably be given as "increase-on" therapy. In Section C, contr